New Treatment Arm Added: Favipiravir

* Favipiravir is an antiviral drug which has been licenced in Japan since 2014 to treat influenza.
* It works by inhibiting a viral enzyme called RNA polymerase, preventing viral replication within human cells. This viral enzyme is common to several viruses, including SARS-CoV-2, which causes COVID-19.
* The drug has shown positive results against SARS-CoV-2 in laboratory and animal studies, with small pilot studies in humans demonstrating some benefit in reducing symptoms and the duration of illness.

PRINCIPLE Trial Co-lead Investigator, Chris Butler:
“Until now, we have been testing medicines that have not typically been used to treat viral infections. This is the first drug we will be testing that was designed specifically to target viruses, so we are particularly excited to be including Favipiravir in the PRINCIPLE trial to determine whether it could be used in the community as a COVID-19 treatment and prevent people from getting very sick.”

PRINCIPLE has Recruited 4748 Participants!

Useful Reminder - The PRINCIPLE Trial - Eligibility Criteria

<table>
<thead>
<tr>
<th>Trial arms</th>
<th>Eligible Age Group (meeting eligibility criteria)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usual Care</td>
<td>18 and over, with a certain underlying health condition, OR who have shortness of breath as part of their COVID-19-like illness</td>
</tr>
<tr>
<td>Usual Care + Colchicine</td>
<td>18 and over, with a certain underlying health condition, OR who have shortness of breath as part of their COVID-19-like illness</td>
</tr>
<tr>
<td>Usual Care + Favipiravir</td>
<td>50 – 64 with a certain underlying health condition, OR who have shortness of breath as part of their COVID-19-like illness. OR aged 65 and over</td>
</tr>
</tbody>
</table>

Meet the Team - Nicola Maeder—Trial Co-Ordinator

Why did you get into research?
After many years teaching I was looking for a change and began working at the CTU on a temporary basis. I liked it so much I stayed!

What’s your favourite thing about working at the CTU?
While the work is interesting, it’s my colleagues at the CTU who make it so enjoyable.

What have you learnt about working on PRINCIPLE?
Having been involved in many parts of the trial process, I have learnt a lot, but I think with much of the team working remotely, we have all adapted well with the help of technology.